100313-75-5

Upstream product

• 619-19-2 2-hydroxy-4-nitrobenzoic acid 
• 17336-10-6 2-acetoxy-4-nitrobenzoic acid 

Downstream Products

• 78154-69-5 1-(2-hydroxy-4-nitro-benzoyl)-piperidine 
• 858479-10-4 2-hydroxy-4-nitro-benzoic acid thiazol-2-ylamide 
• 857756-46-8 2-hydroxy-4-nitro-benzoic acid pyrimidin-2-ylamide 
• 873401-46-8 2-hydroxy-4-nitro-benzoic acid-(5-methyl-[1,3,4]thiadiazol-2-ylamide) 
• 874501-34-5 2-acetoxy-4-nitro-benzoic acid p-toluidide 
• 110181-73-2 (2-acetoxy-4-nitro-benzoyl)-urea 
• 108302-75-6 N-(2-hydroxy-4-nitro-benzoyl)-glycine 
• 129175-85-5 (S)-2-(2-Acetoxy-4-nitro-benzoylamino)-pentanedioic acid diethyl ester 
• 279215-22-4 N-(4-cyano-phenyl)-2,N-dihydroxy-4-nitro-benzamide 
• 78154-65-1 4-amino-2-hydroxy-benzoic acid anilide 
• 714252-08-1 (2-hydroxy-4-nitro-phenyl)-acetic acid 
• 7414-98-4 N-(4-amino-2-hydroxy-benzoyl)-glycine 
• 857556-61-7 (2-acetoxy-4-nitro-phenyl)-acetic acid methyl ester 

Relevant academic research and scientific papers

Demonstrating Ligandability of the LC3A and LC3B Adapter Interface

Autophagy is the common name for a number of lysosome-based degradation pathways of cytosolic cargos. The key components of autophagy are members of Atg8 family proteins involved in almost all steps of the process, from autophagosome formation to their selective fusion with lysosomes. In this study, we show that the homologous members of the human Atg8 family proteins, LC3A and LC3B, are druggable by a small molecule inhibitor novobiocin. Structure-activity relationship (SAR) studies of the 4-hydroxy coumarin core scaffold were performed, supported by a crystal structure of the LC3A dihydronovobiocin complex. The study reports the first nonpeptide inhibitors for these protein interaction targets and will lay the foundation for the development of more potent chemical probes for the Atg8 protein family which may also find applications for the development of autophagy-mediated degraders (AUTACs).

FUSED BICYCLIC COMPOUND

The present invention provides a novel fused bicyclic compound having an affinity to a receptor of mineral corticoid (MR), shown by the formula [I]: wherein the ring A is a benzene ring having a substituent R1, fused to an adjacent 6-membered h

The first general synthesis of N-substituted 1,2-benzisoxazolin-3-ones

A convenient synthesis of the title compounds has been developed. Key synthetic steps include: (1) conversion of the readily available salicylic acid derivatives to the corresponding N-substituted salicylhydroxamic acids; (2) cyclization of the hydroxamic acids under Mitsunobu conditions to give the title compounds. (C) 2000 Elsevier Science Ltd.

Quinazoline antifolate thymidylate synthase inhibitors: Benzoyl ring modifications in the C2-methyl series

The synthesis of nine new 2-methyl-10-propargylquinazoline antifolates with substituents in the p-aminobenzoyl ring is described. In general the synthetic route involved the coupling of the appropriate ring-substituted diethyl N-[4-(prop-2-ynylamino)benzoyl]-L-glutamate with 6-(bromomethyl)-3,4-dihydro-2-methyl-4-oxoquinazoline (11) followed by deprotection using mild alkali. The compounds were tested as inhibitors of partially purified L1210 thymidylate synthase (TS). They were also examined for their inhibition of the growth L1210 cells in culture. Compared to the parent compound 1a the 2'-fluoro analogue 2a exhibited enhanced potency in both systems whereas the 3'-fluoro analogue 3a showed enhanced growth inhibitory properties against L1210 cells despite being a poorer inhibitor of the isolated enzyme. Chloro, hydroxy, methoxy, and nitro substituents in the 2'-position were also well tolerated by the enzyme but failed to give enhanced growth inhibition. The series was extended to cover analogues of the 2'-fluoro, 3'-fluoro, 2'-chloro, 2'-methyl, 2'-amino, 2'-methoxy, and 2'-nitro derivatives with modified alkyl substituents at N10.